Lineage specification demands precise and tightly coordinated patterns of gene expression that dictate cell fate choices. In metazoans, cell type specificity of gene expression patterns is largely regulated by distal regulatory elements, called enhancers. Similar to promoters, enhancers harbor arrays of sequences that are recognized by multiple transcription factors (TFs), but unlike promoters, enhancers can activate transcription independent of their location, distance, or orientation with respect to the transcription start site (TSS) of each gene (reviewed in refs. [@R1]--[@R4]). Seminal studies have revealed that chromatin states at promoters are highly correlated across different cell types, whereas histone modifications at enhancers are frequently cell type-specific and tightly associated with gene expression patterns.[@R5]^,^[@R6] This fundamental observation suggests that enhancers can be regarded as a major determinant of cell type-specific gene expression in mammalian genomes. Indeed, evidence is emerging that due to their potent effect on gene transcription, enhancers are capable of influencing a variety of fundamental cellular phenomena, including stem cell multipotency[@R7]^,^[@R8] and nuclear and chromosomal architecture.[@R9]^,^[@R10]

Along these lines, aberrant enhancer function was recently demonstrated to have important implications for human disease and development. It has been estimated that the total coverage of human enhancers amounts to nearly 10% of the human genome, representing a 5-fold greater coverage compared with protein-coding sequences.[@R2] Although most well established disease-related mutations are within protein-coding sequences, it is logical to assume that mutations within enhancers could similarly result in human disease. These mutations could impair recruitment of TFs to enhancers, potentially disrupting tissue- and lineage-specific gene expression and, consequently, development. Indeed, sequencing analyses and epigenetic comparisons have implicated mutations in non-coding distal enhancers as a pathological basis of multiple diseases and cancer.[@R11]^-^[@R15] In addition, single-nucleotide polymorphisms (SNPs) can confer genetic variation within enhancers as a result of altered TF binding to enhancer sites. For example, recent studies have demonstrated that a single nucleotide alteration in the enhancer of the sodium channel gene, *SCN10A*, functionally disrupts TBX3/TBX5 binding and leads to reduced cardiac activity of this enhancer in vivo.[@R16] In another report, allelic variation in a common non-coding SNP located in the distal enhancer of the pigment gene, *OCA2*, was shown to disrupt its regulatory function and promoter interactions, resulting in allelic gene expression differences that influence pigmentation.[@R17]

Given the essential function of enhancers, it is important to comprehensively deduce the locations of these elements in each cell type. It is now clear that deposition of monomethylated H3K4 (H3K4me1), coupled with robust acetylation of histone H3K27 (H3K27ac), constitutes a predominant chromatin "signature" for transcriptional enhancers associated with actively transcribed genes.[@R18]^,^[@R19] Recruitment of enzymes that facilitate this unique set of histone modifications, such as histone acetyltransferases, p300 and CREB binding protein (CBP),[@R20] which acetylate H3K27, and methyltransferases Set7,[@R13] MLL3 and MLL4,[@R14] which monomethylate H3K4, are also associated with active enhancers. Transcriptional enhancers were further shown to recruit RNA polymerase II (RNAP II), and such recruitment is associated with transcription of small RNAs and large non-coding RNAs.[@R20]^,^[@R21] These observations, catalyzed by the advent of massively parallel sequencing, have accelerated enhancer identification and analysis and allowed enhancer mapping in numerous cell types, including forebrain,[@R22] cortical neurons,[@R20] bone marrow macrophages,[@R23] heart,[@R24]^,^[@R25] and adipocytes.[@R26] Tissue-specific TF binding represents an additional attribute of active enhancers, and it is logical to postulate that such TFs facilitate recruitment of histone-modifying enzymes.[@R8] Motif searches on genomic regions identified by ChIP-seq analysis as potential enhancers reveal the recruitment of cell type-specific TFs that were previously implicated as essential regulators of lineage-specific differentiation. This list of factors includes Foxa1 and Foxa2 in liver cells,[@R8]^,^[@R27] PU.1 in pro-B lymphocytes,[@R23] Rfx1 in neural progenitors,[@R8] and STAT1, 4 and 6 proteins in T cells,[@R28] among others. Thus, the recent discovery of the role of these TFs positions them as critical master regulators of enhancer activity.

Based on the combination of chromatin marks observed in a given state, distal enhancers can be separated into several classes: "active" enhancers marked by H3K4me1 and H3K27ac, "inactive" (or "poised") enhancers associated with H3K4me1 but not H3K27ac, and "latent" enhancers, which, in terminally differentiated cells, are not bound by TFs and lack the histone marks characteristic of enhancers but are capable of rapidly acquiring both features in response to specific stimuli.[@R8]^,^[@R29]^-^[@R31] Thus, prior to their differentiation into pro-B lymphocytes, liver, or neuronal cells, ES cells contain poised enhancers that are converted to their active state upon differentiation.[@R8] Complementary evidence showed that in addition to H3K4me1 (and the absence of H3K27ac), poised enhancers in ES or undifferentiated cells are associated with the repressive modification H3K27me3.[@R30]^,^[@R32] Interestingly, epigenetic studies in pluripotent ES cells have shown that during the earliest stages of development, poised enhancers are bound by pioneer factors (also known as "place-holders") that act to maintain developmental enhancers in a poised/inactive state.[@R2]^,^[@R3]^,^[@R33] Upon differentiation, and depending upon the lineage that is adopted, the presence of such factors at enhancers decays, concomitant with the appearance of a master regulator and chromatin marks signifying an active enhancer. Thus, upon differentiation of ES cells into endoderm, FoxD3 is replaced by the activating factor, FoxA1[@R27]; in addition, upon differentiation to neurons, Sox2 is replaced by Sox3 and Sox11.[@R34] Although the biology of placeholders needs further exploration, one critical aspect is their timely replacement by enhancer activating factors and the acquisition of active enhancer signature. It is possible that defects in this transition could be deleterious to differentiation, as they are likely to lock cells in a proliferative state, which could promote cancer.

MyoD1 as a Central Regulator of Active Muscle Enhancers
=======================================================

MyoD1 is a key master regulator of skeletal muscle differentiation,[@R35] and its role in myogenic differentiation[@R36] and trans-differentiation of fibroblasts[@R37] and other cell types[@R38] has been well established. Indeed, enforced expression of MyoD1 alone is sufficient to trans-differentiate fibroblasts and other cell types to muscle.[@R36]^-^[@R38] Upon induction of differentiation, MyoD1 interacts with E-proteins to form DNA-binding heterodimers that synergistically activate promoter-specific transcription of myogenic genes[@R39] in a temporally defined manner.[@R40] The MyoD1:E-protein heterodimer complex exhibits preference for an E-box element with the VCASCTGT consensus sequence (where V stands for A, C or G, and S stands for C or G), which was found to be enriched within promoter and enhancer regions associated with muscle-related genes.[@R41]^-^[@R44] In addition, in vivo[@R45] and in vitro[@R46]^,^[@R47] reporter assays established that MyoD1 activates transcription of genes containing multiple E-box motifs. Although the mechanisms by which MyoD1 contributes to muscle differentiation have primarily focused on promoter regulation, classical enhancer-reporter assays revealed a dependence on MyoD1 for enhancer activity as well. Enhancer regions critical for the myogenic program and enriched with E-box elements that recruit MyoD1 have been identified distal to the *myogenin*,[@R48]^,^[@R49] *MyoD1*,[@R50] *myosin chain 1*,[@R51]^-^[@R53] *Ckm*,[@R54]^,^[@R55] *Myf5* and *Mrf4*,[@R56]^,^[@R57] *γ-sarcoglycan*,[@R58] *Id1*[@R59] and *Adamts5*[@R60] genes.

To identify active enhancers in skeletal muscle genome-wide and to elucidate the molecular mechanisms that regulate their activity during differentiation, we recently performed ChIP-seq analysis (high-throughput sequencing of DNA enriched by chromatin immunoprecipitation) on four of the well-established enhancer marks (H3K4Me1, H3K27ac, p300 and RNAP II) before and after myogenic differentiation.[@R61] Our analysis revealed that the total number of muscle enhancers increased throughout differentiation from approximately 4,000 in myoblasts to as many as 1.5-times that number in myotubes. Of these, \~3,000 were exclusively active before differentiation, and \~5,000 were only active after differentiation (whereas the remaining enhancers were constitutively marked in both conditions). Interestingly, this finding is in line with the previously known increase in active enhancer assembly in the transition from blastula to gastrula stages[@R31] and from embryonic stem cells (ESC) to neuronal progenitor cells (NPC),[@R8] and thus, it may reflect a general feature of enhancers related to differentiation. Our compendium of distal enhancers recovered many previously identified enhancer regions, and overall there was a strong correlation between the activity of condition-specific enhancers and the transcription level of their adjacent genes, indicating that these enhancers augment transcription of thousands of protein-coding genes. Consistent with other tissue-specific elements whose evolution occurs at higher rates,[@R62]^,^[@R63] we have shown that muscle-specific enhancers are strongly- but not ultra-conserved.[@R61]

Furthermore, by linking condition-specific enhancers to their nearest associated condition-specific genes, we showed that the median enhancer-promoter distance for myotubes was significantly shorter (by more than 13 kb) than the corresponding distance in myoblasts, suggesting that reduction in the distances between enhancers and their active, linked promoters may also be a characteristic of muscle differentiation. Future studies will determine whether this reduction could be related to differentiation-dependent, architectural changes in chromatin. In addition, approximately 10% of our condition-specific enhancers were associated with non-coding transcripts,[@R64] and \~60% of these enhancers displayed significant levels of RNAP II recruitment. These findings are in line with previous reports that suggest a cis-regulatory role for transcripts emanating from enhancers.[@R20]^,^[@R21]

In-silico analysis indicated that nearly half of myoblast-specific and approximately 80% of myotube-specific enhancers exhibited predicted MyoD1 binding sites.[@R61] However, overlap of our enhancer data sets with experimentally determined MyoD1-binding events[@R44] revealed that approximately 30% of condition-specific enhancers were bound with MyoD1, suggesting that additional epigenetic cues, such as binding of sequence-specific factors and/or chromatin architecture, dictated by histone modifications, play an important role in limiting MyoD1 recruitment to muscle enhancers. The strong trans-activation potential of MyoD1 at muscle enhancers is likely augmented through its ability to interact with multiple transcriptional regulatory factors. Motif enrichment analysis of ChIP-seq data sets indicated that sequence-specific TFs can be recruited in a spatially constrained manner around MyoD1-binding sites. Importantly, several of these identified TFs, such as Jdp2,[@R65] Meis,[@R66] c-Jun,[@R67] and Runx1,[@R68] are well known regulators of myogenesis, and in the absence of MyoD1, the recruitment of these factors, as well as RNAP II, was dramatically reduced at MyoD1-bound enhancers ([Fig. 1](#F1){ref-type="fig"}). These findings suggest that MyoD1 plays an essential role in enhancer assembly by recruiting TFs that have established roles in muscle differentiation. Indeed, genome-wide analysis of c-Jun binding sites in myoblasts indicated that MyoD1 and c-Jun co-localize within a narrow window on 54% of muscle enhancers.[@R61] Further, suppression of c-Jun expression in myoblasts led to strong reductions in the levels of H3K4me1 and H3K27ac at selected myoblast enhancers bound by c-Jun but not at other enhancers that were not bound by this TF.[@R61] These studies, which strongly suggest that MyoD1 and c-Jun coordinately regulate enhancer assembly, are consistent with biochemical studies showing that these proteins interact in vitro.[@R67] It will be interesting in the future to determine whether mutations and SNPs that map to our compendium of enhancers---particularly those that map to MyoD1, c-Jun, and other factor binding sites---could underlie human skeletal muscle disease.

![**Figure 1.** Model for the coordinate assembly of active MyoD1 enhancers in muscle. (**A**) MyoD1 co-binds to enhancers in conjunction with a putative pioneer factor ("placeholder") that maintains them in a poised/inactive state. (**B**) Eviction (or inactivation) of enhancer-bound placeholder allows the recruitment of other transcription factors that positively regulate enhancer activity, leading to acquisition of a transcriptionally active state, characterized by deposition of H3K4me1 and H3K27ac and often in non-coding transcription. See text for further details.](epi-8-778-g1){#F1}

Several studies have indicated that once tethered to its binding sites at promoters, MyoD1 recruits the acetyltransferases, p300 and PCAF, leading to acetylation of histones H3 and H4[@R44]^,^[@R69]^-^[@R73] and MyoD,[@R47]^,^[@R74] respectively. Our analysis indicated that the overwhelming majority of condition-specific enhancers bound by MyoD1 were co-occupied by p300. Statistically, the fraction of MyoD1-bound enhancers that recruit p300 was significantly higher than the fraction of MyoD1 enhancers that lack p300, suggesting that MyoD1 might have a strong impact on p300 recruitment to active muscle enhancers. Indeed, MyoD1-null myoblasts exhibited sharply diminished levels of p300 and H3K27ac at each of the MyoD1-bound enhancers that we tested.[@R61] qChIP experiments revealed that Set7 was recruited to muscle enhancers in a MyoD1-dependent manner, since recruitment of Set7 and deposition of H3K4me1 were significantly diminished at MyoD1-bound enhancers in *MyoD1^−/−^* myoblasts, as compared with their wild-type counterparts.[@R61] These results are consistent with another study that demonstrated direct MyoD1-Set7 interactions on the MCK enhancer and delineated the importance of Set7 for promoting myoblast differentiation via regulation of H3K4me1 deposition.[@R75] Furthermore, we detected MyoD1-independent recruitment of Set7 to enhancers, suggesting that this methyltransferase may be recruited by TFs other than MyoD1. Despite these observations, one important question---the functional role of mono-methylation of H3K4 in enhancer regulation---will need to be addressed to complete our understanding of MyoD1 function.

Another intriguing question pertains to the role of placeholders as regulators of the myogenic program. It is interesting to speculate that myogenic muscle precursor cells (myoblasts) found within the developing limb bud and regenerating satellite cells might show widespread binding of such putative factors to their enhancers ([Fig. 1](#F1){ref-type="fig"}). In each of these cases, MyoD1 is expressed at high levels, yet these populations remain undifferentiated until appropriate environmental conditions are satisfied. Attempts to identify a specific modification that can convert MyoD1 from an inactive to an active form have not succeeded.[@R76] Of note, our studies have shown that among MyoD1-bound enhancers that become exclusively active in myotubes, the majority of them (\~72%), are already bound by MyoD1 in myoblasts, prior to their assembly into active enhancers.[@R61] These results suggest that in many cases, binding of MyoD1 by itself is not sufficient to promote the transition to an active enhancer, and it is plausible that an additional trigger is required to facilitate the removal or acquisition of a specific factor that co-occupies the enhancer with MyoD1. It is possible that co-repressors (or other placeholders) can suppress the action of MyoD1 bound to muscle enhancers before it becomes active.[@R33]^,^[@R77]^,^[@R78] Future investigations into how placeholders restrain the transcriptional activity of MyoD1 (and possibly other myogenic regulatory factors, MRFs) will greatly advance our understanding of mechanisms through which the myogenic program is induced.

Signaling to Enhancers: Conversion to an Active or Inactive State
=================================================================

Recent studies have delineated the signaling pathways that govern specification of mesodermal precursor cells into myoblasts and subsequently into differentiated myotubes (reviewed in ref. [@R79]). Such specification of these precursor cells, located in the dorsal region of the somites (dermomyotome), into myoblasts is mediated by a variety of molecular signals emanating from surrounding tissues. A combination of stimulatory signals, including Wnts, Sonic hedgehog (Shh), and Noggin, and suppressive signals, such as BMP4, ultimately dictate expression patterns of the primary MRFs, MyoD1 and Myf5, and therefore propel commitment to the myogenic fate. In the lateral part of the dermomyotome, myoblasts that preferentially express MyoD1 migrate to form the myotome, which eventually forms the skeletal musculature. Increased expression of the secondary MRFs---myogenin and MRF4---stimulates the next step in myogenesis, as skeletal myoblasts fuse and eventually form bundles of multinucleated myofibers.[@R79]

Several studies suggest that extracellular signals could ultimately be converted into epigenetic modifications that directly affect transcription. For example, one of the major pathways associated with muscle differentiation is the p38 MAP kinase signaling cascade. At the onset of differentiation, p38 is activated and phosphorylates E47 at Ser140, leading to its dimerization with MyoD1 and to subsequent binding to E-box motifs of different muscle promoters.[@R80] In addition, phosphorylation of the SWI/SNF component, BAF60, by p38α/β stimulates the recruitment of this multi-subunit chromatin-remodeling complex to regulatory regions of muscle-specific genes.[@R71] Further, forced inhibition of p38α/β blocks the engagement between MyoD1 and BRG1 and BRM, two ATPase subunits of SWI/SNF.[@R71] Another aspect of p38 activity is its ability to directly phosphorylate the transactivation domains of MEF2A and MEF2C, which, through interactions with MyoD1, results in stimulation of their transcriptional activity.[@R81]^-^[@R84] By contrast, p38γ is known to phosphorylate MyoD1, resulting in its enhanced promoter occupancy but reduced transcriptional activity.[@R85] Another signaling pathway that is known to mediate intracellular events in response to external growth factors, such as IGF1, is PI3K/AKT signaling. This pathway, known to function in parallel with the p38 cascade during early myogenic differentiation, is critically involved in activation of muscle differentiation,[@R86] muscle cell survival,[@R87] and regeneration.[@R88]^,^[@R89] Consistent with this notion, suppression of each of these pathways was shown to alter the patterns of specific chromatin modifiers on the *Mck* enhancer.[@R90]

Given the fact that MyoD1 plays a prominent role at enhancers, and since several of these signaling pathways impinge on MyoD1 activity, it is reasonable to postulate that these cascades may indeed regulate MyoD1 activity at enhancers, converting them to an activated or inactivated state. Thus, although the mechanisms through which these signaling pathways participate in regulation of enhancer activity remain largely unknown, future studies will determine the extent to which these signaling pathways play a role at enhancers, before and during muscle differentiation.

Conclusion
==========

In summary, we propose that while MyoD1 binds to a large number of promoters that augment expression of genes essential for specifying the muscle lineage, a key role for this factor appears to be its ability to bind to enhancers. Our model establishes a role for MyoD1 in mediating the co-recruitment of several chromatin modifying enzymes, among them Set7 and p300, which subsequently deposit the histone marks that typify active enhancers ([Fig. 1](#F1){ref-type="fig"}). Importantly, several TFs, including c-Jun, are recruited to active enhancers bound by MyoD1, suggesting that interactions between MyoD1 and other TFs are necessary for assembly of active enhancers. Interestingly, unlike MyoD1, whose expression is restricted to skeletal muscle, c-Jun is expressed in multiple tissue types. Thus, it is interesting to speculate that in other tissues, alternative bHLH-type transcriptional activators could collaborate with c-Jun to regulate enhancer activity through a similar mechanism.
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